Home > GAMMAGARD Products > GAMMAGARD LIQUID IV

GAMMAGARD LIQUID IV

Learn more about intravenous (IV) administration of GAMMAGARD LIQUID

Protect life's moments with:



Selected Important Risk Information

  • The serious adverse reaction that occurred during the PI (IV administration) clinical trials was aseptic meningitis.
  • The most common adverse reactions observed in ≥ 5% of patients in the PI (IV administration) clinical trials were: Headache, fatigue, pyrexia, nausea, chills, rigors, pain in extremity, diarrhea, migraine, dizziness, vomiting, cough, urticaria, asthma, pharyngolaryngeal pain, rash, arthralgia, myalgia, oedema peripheral, pruritus, and cardiac murmur.

References: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc. 2. Church JA, Leibl H, Stein MR, et al, and the US-PID-IGIV 10%-Study Group. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IVIG 10%] in patients with primary immunodeficiency. J Clin Immunol. 2006;26:388-395.


  • Your patients can get access to experienced Patient and Nurse Advocates, insurance and financial support, useful tools, and more.
    Find Out How
  • Infusion Training Get training support from our Nurse
    Advocates on intravenous and subcutaneous administration of GAMMAGARD LIQUID.

    Call 1-855-250-5111 to talk to a
    Nurse Advocate
Error processing SSI file